The Legacy of Daniel Andrews: Recognising the Good…

Today the impending retirement of Daniel Andrews – Labor Premier of Victoria…

Study reveals most common forms of coercive control…

Media Release A new study by the NSW Bureau of Crime Statistics and…

Great Expectations from the Summit of the G-77…

By Denis Bright The prospects for commitment to UN General Assembly’s sustainment development…

Imperial Footprints in Africa: The Dismal Role of…

No power in history has exercised such global reach. With brutal immediacy,…

Fascism is unlikely: idiocy is the real threat

The fight against domestic fascism is as American as apple pie. Even…

Murdoch: King Lear or Citizen Kane?

By guest columnist Tess Lawrence It may be premature to write Emeritus Chairman…

"This Is All A Giant Push By (INSERT…

"Beer?" "Thanks" "So what you been up to this week?" "I went on a march…

Dutton reminds us of Abbott, but not in…

Reading Nikki Savva’s The Road to Ruin is a depressing read, because it validates…


Trouble in Vaccine Land: The Wiliness of South Africa’s Coronavirus Variant

It began as a shudder through the scientific and public health establishments. A new variant of the novel coronavirus SARS-CoV-2 had been found, mutating in South African climes, potentially outwitting human responses to it. Vaccines such as Oxford-AstraZeneca’s would have to be brushed up. Rollouts would have to be reconsidered.

The South African variant has been given a few designations: 501Y.V2 or B.1.351. Within it lies a mutation – N501Y – which suggests a greater degree of contagiousness. Another, E484k, might bypass the human immune system, thereby blunting the effectiveness of the vaccines.

A study on the effectiveness of the Pfizer vaccine against N501Y and E484k mutations found that the vaccine did still work, but with less efficacy. The authors of the study treaded carefully, making it clear that the study had made assumptions about levels of neutralisation. The biological functions of N501Y and other mutations also remained “to be defined for viral replication, pathogenesis, and/or transmission in animal models.”

The concern for the Oxford-AstraZeneca vaccine is graver, given that it was deemed the great hope for developing countries, with lower pricing and less demanding conditions for storage. Preliminary, and yet to be peer-reviewed research of some 2,000 individuals, has found the vaccine to have less impressive protections (under 25%) against mild-to-moderate illness caused by the 501Y.V2 variant.

The same cannot be said about protecting against severe COVID-19, an open point given that those recruited in the study were generally healthy, young and sporting only mild symptoms. None required hospitalisation. Such qualifications were seized upon by World Health Organization’s Director-General, Tedros Adhanom Ghebreyesus. “Given the limited sample size and the younger, healthier profile of the participants it is important to determine whether or not the vaccine remains effective in preventing more severe illness.”

Despite this not entirely gloomy picture, politicians in South Africa have been bitten by fear. As the country most affected on the African continent, doses of the Oxford-AstraZeneca vaccine are being traded in favour of Johnson & Johnson shots. The latter vaccine has also been shown in trials to be less effective in combating the mild aspect of 501.V2 (57%) though does a much better job of combating instances of severe disease (85%).

The announcement of this policy shift came from the Health Minister Zweli Mkhize on February 10: “Given the outcome of the efficacy studies [the government] will continue with the planned phase one vaccination using the Johnson & Johnson vaccines instead of the AstraZeneca vaccine.”

This would have delighted the J&J crew, given that the one-shot vaccine has only been approved for use in studies in South Africa and has yet to be officially authorised for general use in any country. Applications for emergency use from South Africa’s regulatory authority and the US Food and Drug Administration have been made. Not to worry, claimed Mkhize: the vaccine had been tested on 44,000 people so far; safety for intending recipients was assured.

The health minister was also keen to give the impression of business. “Our scientists are continuing to evaluate other [vaccine] candidates and we are simultaneously engaging manufacturers. We are in advanced stages of evaluating and engaging the manufacturers of the Sputnik V candidate. Engagements with Sinopharm continue, with an offer already made by China for vaccines which are being considered.”

The move has not convinced certain health practitioners. Sipho Dinabantu of Chris Hani Baragwanath Hospital is worried that “that trust we had in the government to do a proper vaccination program” has evaporated. “We were given assurances that it was ready to go but now it has been put on hold. It makes me wonder a lot about the Johnson & Johnson vaccine, which has yet to be approved.”

The risk of waste is a serious one. A million Oxford-AstraZeneca vaccines have been procured from the Serum Institute of India. These are due to expire at the end of April. Shabir Madhi of the University of Witwatersrand, the lead investigator of the South African trials of that vaccine, finds it rather daft that these would not be used, despite acknowledging its weaknesses. “It doesn’t make any sense to have 1 million doses of vaccine available to us known to be safe and to not start distributing it at least for high-risk groups.” The country’s elderly and those with comorbidities could receive those shots.

Mkhize hopes that these might be sold or swapped depending on what the Ministerial Advisory Committee suggests. Countries were already making inquiries. But there are concerns that expired vaccines might also find their way into the program. We only have Mkhize’s assurance that the vaccines had not expired, and would not be administered if they had.

Confidence in public health authorities has again received a bruising, though the South African government has its defenders. Professor Willem Hanekom, director of the Africa Health Institute, was all praise at the decision to embrace the J&J option. “We’ve never been in such a situation. Every day things change, and we need to adapt to these changes.” The trend of treating whole populations as guinea pigs in a grand public health experiment continues.

Like what we do at The AIMN?

You’ll like it even more knowing that your donation will help us to keep up the good fight.

Chuck in a few bucks and see just how far it goes!

Donate Button


Login here Register here
  1. wam

    Too good for me, dr kampmark.
    I stick with anything scummo’s mob does is of a less efficacy than their usual offering of nothing

  2. Andrew J. Smith

    Keeping in mind the science issues of mutation, it’s a godsend for many PMs or leaders who can use mutated variants as an excuse for sub-optimal responses and/or arse covering.

  3. Joseph Carli

    Thankfully, I live out in the splendid isolation…the only sick people I meet are those on social media…and they can be easily “cured”.

  4. king1394

    The general population has been propagandised to believe that all “vaccines” are 100% safe, totally effective, and side-effects are very mild. Anyone who voices reservations is immediately labeled “anti-vax” and lumped in with flat-earthers, and climate change deniers, as anti-science conspiracy theorists, who are gullible fools. Between the photos of polio wards crammed with iron lungs, and common ideas about herd immunity, any reservations about the perfect nature of vaccines are overwhelmed by what are
    quite emotional arguments that imply that everyone has an obligation to be vaccinated to protect little babies, and the immuno-compromised, and that anti-vaxxers are akin to murderers.
    But now we are able to observe the process behind rushing a number of inadequately tested experimental vaccines to market, and it makes me, for one, and a lot of others, feel very uneasy about the general safety and long-term effects of accepting the new vaccination. Apparently, the different vaccines have various levels of efficacy, against what are turning out to be a number of vaccine strains; additionally, one hears that some of the aspects of the handling of the vaccine i.e. keeping it very cold, managing multi-use vials, are also challenging and not studied as yet. Further, the suggestion that there will be a certification process to track (or label) those who have been vaccinated, also gives pause.
    It makes me feel strong resistance to accepting the vaccine in Australia.

  5. guest

    Your first sentence says: “The general population has been propagandised to believe that all ‘vaccines’ are 100% safe, totally effective, and side-effects are very mild.” Later, you say: Apparently, the different vaccines have various levels of efficacy…” It seems rather contradictory.

    And while you say “what are quite emotional arguments” obliging us to take the vaccines, your own expression of doubt here is itself an “emotional argument”.

    But I am not surprised because we have all been bombarded with alternative points of view all claiming veracity. So I wonder about the veracity of claims for the efficacy of, say, hydroxychloroquine or ivermectin. Craig Kelly has spoken about these two drugs. He says he is supported by immunologist Robert Clancy of the University of Newcastle, who says he does not support everything Kelly says. The University of Newcastle has distanced itself from Professor Clancy. (Nicholas Jensen, The Australian, 7/2/2021)

    Also in The Australian (8/2/2021), Chris Mitchell says:”This column often argues journalists are too lazy to read the science of climate change for themselves. Ditto COVID-19 science, as last week’s media pile-on against Sydney federal Liberal MP Craig Kelly showed.”

    For Mitchell, the climate science might be the same as the IPA publication for 2017 where the editor admits its articles have many contradictions, but it is hoped they will one day be reconciled. Not so scientific at all.

    He might also rely on the claims of a website (or similar) such as Frontier Centre for Public Policy, a Canadian think-tank which is seen as neo-liberal or right libertarian, funded by Heartland (Wikipedia).

    This site says much the same as Mitchell about how much hydroxychloroquine is used around the world, because it is cheap, they say, and effective. It has become politicised, they say, because Trump claimed to have used it.

    However, when hydroxychloroquine is being used for treatment of rheumatic problems, it must be used under strict supervision, is slow to take effect on rheumatic problems and has side effects on the heart, for example. Experiments with HCQ and COVID-19 have raised more questions than answers. (>drug safety – 1/7/2020)

    Mitchell says we must all question scientists, and he may be right. But when he doubts the veracity of epidemiologists because they are not consistent in all states at the same time, or the science does not support the edict – that is, they tailor their advice to the state, I know he is just being contrarian.

    I would follow the epidemiologists rather than a journalist. And I will be watching for scientific advice on the efficacy and side-effects of any vaccines offered to me. I will not be getting madly emotional about it.

Leave a Reply

Your email address will not be published. Required fields are marked *

The maximum upload file size: 2 MB. You can upload: image, audio, video, document, spreadsheet, interactive, text, archive, code, other. Links to YouTube, Facebook, Twitter and other services inserted in the comment text will be automatically embedded. Drop file here

Return to home page
%d bloggers like this: